MAIA Biotechnology, Inc.

In a disappointment, Geron Corporation ’s first-in-class telomerase inhibitor imetelstat for anemia in patients with lower risk myelodysplastic syndromes (MDS) will be subject to a US Food and Drug A

In an unexpected twist, Geron Corporation ’s first-in-class telomerase inhibitor imetelstat for anemia in patients with lower risk myelodysplastic syndromes (MDS) will be subject to a US Food and Dru

Biopharma Financing Biopharma financings during the third quarter of 2022 totaled $18.1bn from 236 deals. The largest was a $1.39bn royalty sale by Theravance Biopharma to Royalty Pharma , which acqu

Third Harmonic Bio Inc. could be the first biopharmaceutical company to launch an initial public offering in the US since the end of July and deliver the first biopharma IPO to raise more than $100m